Changes in Hong Kong stocks | Kodi B (02487) rose more than 3%. Recently, CU-40102 was approved for listing by the Macau Drug Administration

The Zhitong Finance App learned that Kodi B (02487) rose more than 3%. As of press release, it had risen 3.77% to HK$1.1, with a turnover of HK$147,400.

According to the news, Cordi-B announced that the Group's CU-40102 (topical finasteride spray) has been approved for marketing by the Macau Special Administrative Region Government Drug Administration. The approved indication is the treatment of androgenic alopecia. This is another major development since CU-40102 obtained marketing approval from the China National Drug Administration and the Department of Health of the Hong Kong Special Administrative Region Government.

As an important product of the Group that has received marketing approval in the field of hair diseases and care, CU-40102 is being extensively commercialized in China. This approval will further deepen the international layout of CU-40102, expand the CU-40102 market space, and benefit more androgenic alopecia patients.